UNSPSC 51162417: Guaifenesin/phenylpropanolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE516. This VA Drug Class (RE516) classifies this compound as belonging to the group DECONGESTANT/EXPECTORANT.

UNSPSC 51162417 Guaifenesin/phenylpropanolamine is a Commodity code that captures state and local procurement of branded and generic over-the-counter and prescription pharmaceutical products, including cough suppressants, decongestants, and combination formulations. Recent solicitations show state and local governments buying naloxone kits, safe drug deactivation systems, and multi-source generic pharmaceuticals through cooperative purchasing agreements and direct competitive bids. Issuing bodies range from county health departments to multistate cooperative purchasing alliances; Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the recent activity. The code captures both direct supply contracts for community health initiatives and manufacturer-level agreements that feed products through authorized wholesalers to participating state and local facilities.

Geographic activity centers on Florida and Minnesota, with the MMCAP solicitation extending to Oregon and other participating states within the cooperative. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the IFB response deadline was July 26, 2023. MMCAP issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities; vendors were required to submit proposals by March 26, 2026, with contract effectiveness targeted for July 1, 2026. The MMCAP procurement required vendors to certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain relationships with at least two of three authorized wholesalers, and accept a 3 percent administrative fee on all purchases.